Proteon Therapeutics Inc. (PRTO) Upgraded at Zacks Investment Research
According to Zacks, “Proteon Therapeutics Inc. is a biopharmaceutical company. The Company is developing pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. It is developing PRT-201, a recombinant human elastase, applied in a single treatment to the external surface of arteries and veins during an open surgical procedure or an endovascular intervention. Proteon Therapeutics Inc. is headquartered in Waltham, Mass. “
Separately, HC Wainwright began coverage on Proteon Therapeutics in a report on Thursday, September 22nd. They set a buy rating and a $18.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $20.80.
Proteon Therapeutics (NASDAQ:PRTO) traded up 0.68% during trading on Wednesday, reaching $8.91. The company had a trading volume of 100 shares. The firm has a 50-day moving average of $8.99 and a 200-day moving average of $8.18. The stock’s market capitalization is $147.75 million. Proteon Therapeutics has a 1-year low of $4.90 and a 1-year high of $17.76.
Proteon Therapeutics (NASDAQ:PRTO) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.05. On average, analysts anticipate that Proteon Therapeutics will post ($1.85) EPS for the current fiscal year.
Several hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in shares of Proteon Therapeutics by 6.3% in the first quarter. Geode Capital Management LLC now owns 45,412 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 2,685 shares in the last quarter. Bridgeway Capital Management Inc. boosted its stake in shares of Proteon Therapeutics by 211.2% in the second quarter. Bridgeway Capital Management Inc. now owns 36,835 shares of the biopharmaceutical company’s stock worth $296,000 after buying an additional 25,000 shares during the period. TFS Capital LLC acquired a new stake in shares of Proteon Therapeutics during the second quarter worth $206,000. Paloma Partners Management Co acquired a new stake in shares of Proteon Therapeutics during the second quarter worth $234,000. Finally, State Street Corp boosted its stake in shares of Proteon Therapeutics by 58.8% in the first quarter. State Street Corp now owns 94,432 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 34,952 shares during the period. 51.54% of the stock is owned by institutional investors.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.